Keith Loria

Brii Biosciences is one of the drug developers working on regimens that would free people living with HIV from daily pills.

UCLA research Beth D. Jamieson explores the relationship between HIV and aging. Recent evidence suggests that HIV may accelerate aging within two or three years of the initial infection.

Although the Oncology Care Model produced some positive results, the value-based care model cost Medicare money. Now attention is turning to its successor, the Enhancing Oncology Model.

The risk of breakthrough was higher in people living with HIV regardless of CD4 count or HIV viral suppression, according to findings reported by researchers at Johns Hopkins.

The new policy removes any restrictions on members of the armed forced who are HIV positive who are asymptomatic and have a viral load that is undetectable.

Itzchak Levy, M.D., is one of Israel’s top HIV clinicians. He led research showing that people living with HIV responded well to the COVID-19 vaccination.

Results may help allay some of the concern that COVID-19 vaccination might not be effective among those living with HIV.

Woman received cord blood stem cell transplant as a treatment for acute myeloid leukemia. No detectable levels of HIV were found for 14 months after cessation of antiretroviral therapy.

Study shows that among men, about one-third of squamous cell carcinoma anal cancers are among people living with HIV.

Research and discussion about the high cancer rates among Black Americans used to be dominated by genetics and the search for biological differences. Now attention has shifted to the social determinants of health.

In people with HIV, killer T cells (CD8+ T cells) lack a protein called CD73, which is necessary for migration and cell movement into the tissue.

Letter from co-chairs Marlene McNeese and John Wiesman urges enforcement of coverage rules, including zero cost sharing for those with private insurance.

The oral run-in period for the injectable is now optional. The FDA also approved a label change that opens the door for adolescents to be treated with long-acting HIV treatment.

Patients with cancer who have a poor prognosis may face obstacles in accessing critical pain medications.

HIV PrEP uptake was highest for White and Black males and lowest for Hispanic males. Meanwhile, Black females had the highest uptake and twice the rate of PrEP uptake of White females.

The proposed funds include $165 million more for the Ryan White HIV/AIDS Program, $47 million more for HIV and hepatitis prevention activities at the Indian Health Service, and $115 million for CDC HIV prevention programs.

Long-acting injectable holds advantages over daily pills for pre-exposure prophylaxis against HIV, says ViiV executive.

The American Cancer Society’s 2022 statistical report shows that the 30-year trend is continuing.

The decades-long quest for a vaccine against HIV has been fruitless so far. Moderna hopes an HIV vaccine that uses its messenger RNA technology will break the losing streak. A phase 1 trial designed to include 56 volunteers has started.

Physicians who are reluctant or even opposed to broad use of pre-exposure prophylaxis (PrEP) against HIV may keep physician assistants and nurse practitioners from prescribing the antivirals that can prevent infection and spread of HIV. Making PrEP an over-the-counter treatment would be one way of increasing access.

Recent treatment may affect the antibody response, particularly among those with hematologic cancers.

Risk is not associated with cardiovascular events such as heart attacks, Kaiser Permanente researchers report.

About 5,000 women living with HIV in the U.S. give birth each year.

Drug manufacturers are developing long-acting, injectable HIV drugs for both treatment and prevention.

Research shows similar results between those with HIV and those without, although 15 years post-kidney transplant, outcomes were worse for people with HIV.

But the future of value-based care in oncology is uncertain with no certain successor to the Oncology Care Model in sight.

Since the COVID-19 vaccinations have been approved, there have been numerous trials that have all concluded that vaccines are safe for people with HIV. These vaccines have been tried on a number of HIV patients and have been found not to cause any alarming negative side effects.

The FDA approved Apretude (cabotegravir extended-release injectable suspension) for pre-exposure prophylaxis (PrEP) for HIV in December. Administered as an injection every other month, Apretude gives people at risk of contracting HIV a PrEP alternative to taking daily pills.

Screening dipped sharply in 2020 because of the pandemic. The rebound this year is uneven and there is still hesitancy.